Retatrutide is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Triple agonism provides inherent synergy — not typically stacked with other GLP-1 or GIP agonists. Proper stacking requires understanding each compound's mechanism and timing.
What Is Retatrutide Stacking?
Stacking means combining Retatrutide with one or more complementary peptides to potentially achieve synergistic effects. Because different peptides work through different mechanisms, strategic combinations can target multiple pathways simultaneously.
Retatrutide (Retatrutide (LY3437943)) is a Triple hormone receptor agonist researched for substantial weight loss (up to 24.2%), improved glycemic control, improved liver steatosis, reduced diabetic kidney disease markers.
What Is the Best Retatrutide Stack?
Triple agonism provides inherent synergy — not typically stacked with other GLP-1 or GIP agonists.
This combination is popular because it targets multiple mechanisms without significant overlap in side-effect profiles.
How Does Retatrutide Stack With CJC-1295?
CJC-1295 (CJC-1295 (Modified GRF 1-29)) is a Growth Hormone Releasing Hormone (GHRH) analog that works through CJC-1295 binds to GHRH receptors on anterior pituitary somatotrophs, stimulating growth hormone synthesis and pulsatile secretion through the cAMP-PKA.
Combined with Retatrutide's effects on substantial weight loss (up to 24.2%), improved glycemic control, improved liver steatosis, reduced diabetic kidney disease markers, this stack covers increased growth hormone secretion, improved body composition, better sleep quality, enhanced recovery, anti-aging effects as well.
Typical stacking protocol: Retatrutide at 4-12 mg weekly (maintenance after titration) once weekly alongside CJC-1295 at 100-300 mcg 1-3 times daily, typically before bed. See our CJC-1295 guide for details.
How Does Retatrutide Stack With Ipamorelin?
Ipamorelin (Ipamorelin) is a Growth Hormone Secretagogue (GHS) / Ghrelin mimetic that works through Ipamorelin selectively stimulates GH release by mimicking ghrelin at the GHS-R receptor on pituitary somatotrophs. Unlike other GHRPs (GHRP-2, GHRP-6,.
Combined with Retatrutide's effects on substantial weight loss (up to 24.2%), improved glycemic control, improved liver steatosis, reduced diabetic kidney disease markers, this stack covers growth hormone release, improved sleep, fat loss, muscle recovery, bone density support as well.
Typical stacking protocol: Retatrutide at 4-12 mg weekly (maintenance after titration) once weekly alongside Ipamorelin at 200-300 mcg 2-3 times daily. See our Ipamorelin guide for details.
How Does Retatrutide Stack With GHRP-2?
GHRP-2 (Growth Hormone Releasing Peptide-2) is a Growth hormone secretagogue, ghrelin receptor agonist that works through Binds and activates the ghrelin receptor (GHS-R), a G-protein coupled receptor on pituitary somatotrophs. Triggers phospholipase C and inositol signal.
Combined with Retatrutide's effects on substantial weight loss (up to 24.2%), improved glycemic control, improved liver steatosis, reduced diabetic kidney disease markers, this stack covers potent GH elevation, lean muscle mass gain, improved recovery, IGF-1 increases, increased appetite, bone density support as well.
Typical stacking protocol: Retatrutide at 4-12 mg weekly (maintenance after titration) once weekly alongside GHRP-2 at 100-300 mcg per injection 2-3 times daily on empty stomach. See our GHRP-2 guide for details.
How Do You Time a Retatrutide Stack?
When stacking, timing each injection based on half-life is important. Retatrutide has a half-life of approximately 4-5 days, which influences when to administer relative to other compounds.
Some researchers inject all peptides at the same time; others stagger by 15-30 minutes. There's limited data on whether timing within the same session matters significantly.
What Should You NOT Stack With Retatrutide?
Avoid stacking peptides with similar mechanisms of action at full doses — this can lead to receptor desensitization without proportional benefit. Also avoid combining compounds where side-effect profiles overlap significantly.
When in doubt, introduce one new compound at a time to isolate its effects before building a full stack.
Calculate Your Retatrutide Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Retatrutide.
Open Calculator →Bottom Line on Retatrutide Stacking
Triple agonism provides inherent synergy — not typically stacked with other GLP-1 or GIP agonists. Start with a single compound, assess response, then add complements.
See our stacking and cycling guide for general principles.
Complete Guide
Retatrutide : Benefits, Dosage, Side Effects & Research
Related Reading
- Retatrutide Dosage Guide
- Retatrutide Benefits
- Retatrutide Side Effects
- Retatrutide Cycle Guide
- Retatrutide Research
- CJC-1295 Complete Guide
Research-Grade Sourcing
If you're going to research Retatrutide, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Retatrutide?
Retatrutide (Retatrutide (LY3437943)) is a Triple hormone receptor agonist. Novel synthetic peptide developed by Eli Lilly targeting GIP, GLP-1, AND glucagon receptors simultaneously. It is researched for substantial weight loss (up to 24.2%), improved glycemic control, improved liver steatosis, reduced diabetic kidney disease markers.
What is the recommended Retatrutide dosage?
Common dosages: 4-12 mg weekly (maintenance after titration) administered once weekly via subcutaneous injection. Cycle length: 48+ weeks (continuous therapy in trials). Half-life: approximately 4-5 days. Use our peptide calculator for exact reconstitution math.
What are the side effects of Retatrutide?
Gastrointestinal effects predominate: diarrhea, vomiting, constipation, nausea. Generally manageable and dose-dependent. Potential pancreatitis risk similar to GLP-1 agonists.
Is Retatrutide safe?
Retatrutide has shown a preliminary safety profile in research. Not FDA-approved as of March 2026. NDA filing expected late 2026-early 2027. All research should follow appropriate safety protocols.